Blueprint vs Eleos Health (2026)
Blueprint and Eleos Health occupy the same clinical space from opposite ends, and choosing between them is really choosing between commercial legibility and published clinical evidence. Blueprint is the bottom up product: self serve for individual therapists and small practices, more than 70,000 mental health professionals reported, usage priced with a free AI native EHR as the on ramp, graded A on commercial transparency and C on clinical evidence. Eleos is the top down enterprise platform: sold to behavioral health organisations, more than 200 reported, with the deepest published evidence in the category, including a randomised clinical trial in the Journal of Medical Internet Research and a real world accuracy study across more than 2.83 million micro dialogues, graded A on evidence and C on commercial transparency. If your failure mode is a contract you cannot price, start with Blueprint. If your failure mode is deploying clinical AI without peer reviewed proof, start with Eleos.
- Commercial legibility decides it: published per clinician pricing, a usage priced Assistant, and a free AI native EHR as the on ramp, the clearest cost picture in behavioral health documentation.
- You are a solo clinician or small practice: self serve deployment through a browser extension or EHR integration with no migration, and note types spanning individual, couples, family, and group therapy plus psychiatry workflows.
- Clinician level adoption at scale: more than 70,000 mental health professionals reported on the platform, with measurement based care tracking and intervention suggestions built in.
- Peer reviewed evidence is your bar: a randomised clinical trial in the Journal of Medical Internet Research, a machine learning study on therapy homework assignment, and a real world accuracy study across more than 2.83 million micro dialogues.
- You run a behavioral health organisation, not a practice: compliance scanning flags documentation errors before claim submission, treatment effectiveness analytics and leadership dashboards cover caseloads, and Eleos Outreach serves field based case managers.
- Language reach in community settings: recognition across more than 150 languages with notes rendered in clinically accurate English, deployed EHR agnostic through a lightweight browser embedding.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Blueprint and Eleos Health are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Blueprint | Eleos Health |
|---|---|---|
| Primary category | Behavioral Health AI | Behavioral Health AI |
| Founded | 2018 | 2019 |
| Headquarters | Chicago, Illinois, United States | Boston, Massachusetts, United States |
| Website | blueprint.ai | eleos.health |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Blueprint its top capability grade on AI Centrality, EHR and Interoperability Depth and Commercial Transparency. Set against Eleos Health, Blueprint grades higher on Commercial Transparency. Its thinnest published disclosure sits on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Eleos Health its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Set against Blueprint, Eleos Health grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose Blueprint or Eleos Health?
On the axes where the AI Health Index separates them, Blueprint grades higher on Commercial Transparency, and Eleos Health grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Eleos Health leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Blueprint and Eleos Health differ most?
The widest separation the AI Health Index records between Blueprint and Eleos Health is on Commercial Transparency, where Blueprint grades A and Eleos Health grades C. That axis sits in the Commercial group, so it should carry the most weight for a buyer whose binding constraint is contracting, scope and what the price actually covers.
Where do Blueprint and Eleos Health grade the same?
The AI Health Index grades Blueprint and Eleos Health the same on several axes, including AI Centrality, AI Governance and Bias Disclosure and EHR and Interoperability Depth. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Blueprint and Eleos Health not disclosed?
At the last review, at least one of Blueprint and Eleos Health published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Ambient Scribes page.
Adoption counts for both vendors are vendor published. Blueprint's clinical evidence grade is C because no peer reviewed outcome study was retrieved, and under this index's methodology scale of use does not substitute for evidence of benefit. Eleos's commercial transparency grade is C because pricing requires a sales conversation.
Neither vendor published a security attestation at last verification, a gap this index has flagged across enterprise behavioral health, and neither publishes the data training and retention disclosure that Mentalyc states; buyers should confirm data terms on the tier they contract.